References
- Power M. J., Fottrell P. F. Osteocalcin: Diagnostic methods and clinical applications. Crit Rev Clin Lab Sci 1991; 28: 287–335
- Ivaska K. K., Hentunen T. A., Vääräniemi J., Ylipahkala H., Pettersson K., Väänänen H. K. Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J Biol Chem 2004; 18: 18361–9
- Garnero P., Grimaux M., Seguin P., Delmas P. D. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 1994; 9: 255–64
- Farrugia W., Melick R. A. Metabolism of osteocalcin. Calcif Tissue Int 1986; 39: 234–8
- Taylor A. K., Linkhart S., Mohan S., Christenson R. A., Singer F. R., Baylink D. J. Multiple osteocalcin fragments in human urine and serum as detected by a mid‐molecule osteocalcin radioimmunoassay. J Clin Endocrinol Metab 1990; 70: 467–72
- Baumgrass R., Williamson M. K., Price P. A. Identification of peptide fragments generated by digestion of bovine and human osteocalcin with the lysosomal proteinases cathepsin B,D, L, H and S. J Bone Miner Res 1997; 12: 447–55
- Srivastava A. K., Mohan S., Singer F. R., Baylink D. J. A urine midmolecule osteocalcin assay shows higher discriminatory power than a serum midmolecule osteocalcin assay during short‐term alendronate treatment of osteoporotic patients. Bone 2002; 31: 62–9
- Ivaska K. K., Hellman J., Likojärvi J., et al. Identification of novel proteolytic forms of osteocalcin in human urine. Biochem Biophys Res Commun 2003; 306: 973–80
- Ivaska K. K., Pettersson K., Nenonen A., et al. Urinary osteocalcin is a useful marker for monitoring the effect of alendronate therapy. Clin Chem 2005; 51: 2362–5
- Roux C., Seeman E., Eastell R., et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004; 4: 433–9
- Hamdy R. C., Chesnut C. H III., Gass M. L., et al. Review of treatment modalities for postmenopausal osteoporosis. South Med J 2005; 10: 1000–14
- Stepan J. J., Vokrouhlicka J. Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis. Clin Chim Acta 1999; 288: 121–35
- Ivaska K. K., Käkönen S., Gerdhem P., Obrant K. J., Petersson K., Väänänen K. Urinary osteocalcin as a marker of bone metabolism. Clin Chem 2005; 51: 618–28
- Akesson K., Käkönen S. M., Josefsson P. O., et al. Fracture‐induced changes in bone turnover: a potential confounder in the use of biochemical markers in osteoporosis. J Bone Miner Metab 2005; 23: 30–5
- Garnero P., Shih W. J., Gineyts E., Karpf D. B., Delmas P. D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693–700
- Black D. M., Greenspan S. L., Ensrud K. E., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349: 1207–15
- Kushida K., Takahashi M., Kawana K., Inoue T. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab 1995; 80: 2447–50
- Halleen J. M., Ylipahkala H., Alatalo S. L., et al. Serum tartrate‐resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral denisty. Calcif Tissue Int 2002; 71: 20–5
- Garnero P., Ferreras M., Karsdal M. A., et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003; 18: 859–67
- Ravn P., Clemmesen B. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Bone 1999; 24: 237–44
- Eastell R., Barton I., Hannon R. A., et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18: 1051–6